Revenue

12 Months Ended

Sep. 30, 2021

Revenue From Contract With Customer [Abstract]

Revenue

3. Revenue

The following table presents the Company’s revenues disaggregated by product classification and by reportable segment:

	Fiscal Year
(In thousands)	2021		2020		2019
Medical Device
Product sales	$	21,777	$	21,608	$	18,617
Royalties		30,781		28,614		34,781
License fees		16,275		12,020		13,678
Research, development and other		9,420		9,159		11,277
Medical Device Revenue		78,253		71,401		78,353
In Vitro Diagnostics
Product sales		24,701		22,709		21,390
Other		2,182		754		334
In Vitro Diagnostics Revenue		26,883		23,463		21,724
Total Revenue	$	105,136	$	94,864	$	100,077

Contract assets totaled $7.1 million and $6.1 million as of September 30, 2021 and 2020, respectively. Fluctuations in the balance of contract assets result primarily from changes in sales-based and minimum royalties earned, but not collected at each balance sheet date due to payment timing and contractual changes in the normal course of business. For discussion of contract liability (deferred revenue) balances and remaining performance obligations, see Note 4 Collaborative Arrangement.

Revenue from customers that equaled or exceeded 10% of total revenue was as follows:

	Fiscal Year
	2021			2020			2019
Abbott		21	%		19	%		19	%
Medtronic		13	%		14	%		14	%